All In Biotech

Drug Trial Radar · NCT07050732

Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons

Immunogenicity and Safety of Multiple-Dose Adjuvanted RSVPreF3 (Arexvy®) Vaccination Among Immunocompromised Persons

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 170 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

170

Planned (sponsor's estimate)

Start

Dec 4, 2025

Primary completion

Apr 2027

Study completion Sep 2028

Sponsor

Lead sponsor
Johns Hopkins UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
GlaxoSmithKline
First posted
Jul 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This clinical trial is being done to learn more about how well a vaccine (Arexvy®) for respiratory syncytial virus, also known as RSV, works in people with weakened immune systems. The main questions it aims to answer are: * Does 1 or 2 doses of Arexvy work better in people with weakened immune systems? * What medical problems do participants have after receiving Arexvy? Participants with weakened immune systems will: * Receive 3 study vaccines over the course of 1 year * Keep a diary of symptoms for 7 days after each vaccine * Have 3 in-person follow up study visits for checkups and tests over the course of 1.5 years * Have 6 phone follow up study visits over the course of 1.5 years

Conditions

  • Respiratory Syncytial Virus (RSV)

Interventions

  • Arexvy (2 doses total)Biological

    Arexvy at enrollment, Arexvy at Day 365

  • Arexvy (3 doses total)Biological

    Arexvy at enrollment, Day 60, and Day 365

  • Arexvy (1 dose total)Biological

    Arexvy at enrollment

  • PlaceboOther

    Placebo vaccine at day 60

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric Mean Titer (GMT) (ED60 RSV A and B)Time frame: At 30 days post 1st and 2nd dose in Arm 1 and Arm 2
  2. Immune response elicited by adjuvanted RSVPreF3 (Arexvy) in immunocompromised adults as determined by titers of neutralizing antibody ED60 against RSV A and BTime frame: At 30 days post 2nd dose (Arm 2) and 30 days post 1st dose (Arm 1)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Johns Hopkins University

    Baltimore, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.